anti-IL-22 antibodies (Pfizer)
N/A
Report date: 2025/03/14 20:00:48
Base Information
Drug Nameanti-IL-22 antibodies (Pfizer)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWyeth Llc
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A